The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Nuvalent, Inc.(NASDAQ:NUVL)


Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant muta...
Website: http://www.nuvalent.com
Founded: 2017
CEO: James Porter
Sector: Healthcare
Industry: Biotechnology
Nuvalent . Number of Twitter Followers
Nuvalent . Op Cashflow Per Share ttm
Nuvalent . Free Cashflow Per Share ttm
Nuvalent . Cash Per Share ttm
Nuvalent . (GAAP) P/E ratio ttm
Nuvalent . P/B ratio ttm
No extra charts and metrics for this ticker.